Molecular Partners AG: Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
(0) Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, MP0317, led to a localized macrophage repolarization and reversion of T-cell suppression. Clinical trials expected to initiate in the second half of 2021 Effector control technologies give new potential for enhancing current and future immunotherapies while reducing toxicities ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 10, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developi...
Source: finanznachrichten.de